Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PICCOLO: Irinotecan +/- Panitumumab or Cyclosporine in Advanced Colorectal Cancer
NCT00389870Phase 3Completed
- Sponsor
- University of Leeds
- Start
- Dec 2006
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of panitumumab and cyclosporine in colorectal cancer (CRC) (3 arms), sponsored by University of Leeds. Primary endpoints: Proportion of patients progression-free at 12 weeks and Overall Survival. Started Dec 2006; status: completed.
02
Drugs
panitumumabcyclosporine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00389870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00389870.